EP0667778A4 - Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene. - Google Patents

Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene.

Info

Publication number
EP0667778A4
EP0667778A4 EP92924379A EP92924379A EP0667778A4 EP 0667778 A4 EP0667778 A4 EP 0667778A4 EP 92924379 A EP92924379 A EP 92924379A EP 92924379 A EP92924379 A EP 92924379A EP 0667778 A4 EP0667778 A4 EP 0667778A4
Authority
EP
European Patent Office
Prior art keywords
oncogene
melanoma
treatment
antisense oligonucleotides
myb proto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92924379A
Other languages
German (de)
French (fr)
Other versions
EP0667778A1 (en
Inventor
Alan M Gewirtz
Bruno Calabretta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Temple University of Commonwealth System of Higher Education
Original Assignee
University of Pennsylvania Penn
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Temple University of Commonwealth System of Higher Education filed Critical University of Pennsylvania Penn
Publication of EP0667778A1 publication Critical patent/EP0667778A1/en
Publication of EP0667778A4 publication Critical patent/EP0667778A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP92924379A 1991-11-15 1992-11-12 Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene. Withdrawn EP0667778A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79299991A 1991-11-15 1991-11-15
PCT/US1992/009656 WO1993009789A1 (en) 1991-11-15 1992-11-12 Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene
US792999 1997-02-03

Publications (2)

Publication Number Publication Date
EP0667778A1 EP0667778A1 (en) 1995-08-23
EP0667778A4 true EP0667778A4 (en) 1997-04-16

Family

ID=25158769

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92924379A Withdrawn EP0667778A4 (en) 1991-11-15 1992-11-12 Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene.

Country Status (5)

Country Link
EP (1) EP0667778A4 (en)
JP (1) JPH07501525A (en)
AU (1) AU3070992A (en)
CA (1) CA2123611A1 (en)
WO (1) WO1993009789A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5989849A (en) * 1991-05-09 1999-11-23 Temple University Of The Commonwealth System Of Higher Education Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
WO1995011301A1 (en) * 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5994320A (en) * 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005445A1 (en) * 1988-11-07 1990-05-31 Temple University Of The Commonwealth System Of Higher Education Antisense oligonucleotides to c-myb proto-oncogene and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005445A1 (en) * 1988-11-07 1990-05-31 Temple University Of The Commonwealth System Of Higher Education Antisense oligonucleotides to c-myb proto-oncogene and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LINNENBACH, A. ET AL.: "Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, January 1988 (1988-01-01), WASHINGTON US, pages 74 - 78, XP002025496 *
See also references of WO9309789A1 *

Also Published As

Publication number Publication date
EP0667778A1 (en) 1995-08-23
WO1993009789A1 (en) 1993-05-27
AU3070992A (en) 1993-06-15
JPH07501525A (en) 1995-02-16
CA2123611A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
ZA924937B (en) Catalyst treatment
EP0666923A4 (en) Targeted delivery of poly- or oligonucleotides to cells.
GB9019946D0 (en) Treatment of nucleotide material
ZA919613B (en) Hair treatment composition.
HK19496A (en) Use of 1,2,2,3,3-penta-fluoropropane
EP0667778A4 (en) Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene.
GB2262236B (en) Skin treatment appliance
EP0585399A4 (en) Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene
EP0489846A4 (en) Antisense oligonucleotides to c-abl proto-oncogene
PH31659A (en) Therapeutic nucleotides.
EP0580795A4 (en) Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
GB9027429D0 (en) Effluent treatment
AU5086393A (en) Antisense oligonucleotides to cyclin d1 proto-oncogene
EP0612841A3 (en) Use of fabric treatment compostions.
AU2387292A (en) Antisense oligonucleotides
GB9108786D0 (en) Effluent treatment
GB9109020D0 (en) Modified antisense oligonucleotides
GB9120646D0 (en) Hair treatment composition
AU5136693A (en) Antisense oligonucleotides to b myb proto-oncogene
ZA928765B (en) Novel 3-halo-5-halomethyl-2-oxazolidinones and their use as microbicides.
GB2255725B (en) Liquid treatment
ZA919853B (en) Transdermal delivery of dobutamine.
NZ240384A (en) Epoxycarbacyclin derivatives and their use as precursors.
GB9104175D0 (en) New treatment
IE900057L (en) End-attachment of oligonucleotides to polyacrylamide¹supports.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970228

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19970716